How has been the historical performance of Welcure Drugs?

Answer:The historical performance of Welcure Drugs shows significant changes, particularly in the fiscal year ending March 2025. Breakdown: In the fiscal year ending March 2025, Welcure Drugs reported net sales of 24.55 crore, a notable increase from zero in the previous years. The total operating income also rose to 24.55 crore, compared to only 0.11 crore in March 2022. The company's total expenditure, excluding depreciation, was 23.67 crore, which was significantly higher than the previous years, reflecting increased operational activities. Operating profit (PBDIT) for March 2025 stood at 2.79 crore, a recovery from a loss of 0.14 crore in March 2024. Profit before tax reached 2.78 crore, while profit after tax was reported at 2.17 crore, indicating a positive turnaround from losses in prior years. The earnings per share (EPS) improved to 0.19 in March 2025, compared to a loss of 0.13 in March 2024. The operating profit margin and profit after tax margin were recorded at 3.58% and 8.84%, respectively, both reflecting a strong performance compared to previous years where margins were non-existent. Overall, the data indicates a significant improvement in financial performance for Welcure Drugs in the latest fiscal year.